Frontera Therapeutics has dosed its first patients in a gene therapy trial for the treatment of X-Linked retinitis pigmentosa.
FT-002 is an intraocular injection of recombinant AAV virus carrying the gene that expresses active functional proteins and repairs damaged retinal cell structure and function.
The company said one injection could effectively delay disease progression or restore the patient’s visual function.
one injection could effectively delay disease progression or restore the patient’s visual function
It is Frontera’s third gene therapy product candidate to enter the clinic. According to a news release announcing the trial start, T-002 is a recombinant adeno-associated virus gene therapy drug intended to treat patients with X-linked retinitis pigmentosa (XLRP) caused by RPGR gene mutation. There is no treatment for this disease globally.
“I am very pleased with our speed of execution and the rapid build-up of our medical and clinical operations capabilities,” Frontera’s President and Chief Medical Officer Dr Xinyan Li said.
FT-002 is the first AAV gene therapy drug to be tested in XLRP patients in China and is also a potential first-in-class drug.
